Statistical methods for HIV dynamic studies in AIDS clinical trials

Wu, Hulin
April 2005
Statistical Methods in Medical Research;Apr2005, Vol. 14 Issue 2, p171
Academic Journal
Studies of HIV dynamics in AIDS research are very important for understanding pathogenesis of HIV infection and for assessing the potency of antiviral therapies. Since the viral dynamic results from clinical data were first published by Ho et al and Wei et li, the study of HIV-1 dynamics in vivo has drawn a great attention from AIDS clinicians and researchers. Although the important findings from HIV dynamic studies have been published in many prestigious scientific journals, statistical methods for estimating viral dynamic parameters have not been paid enough attention by HIV dynamic investigators. The estimation methods in many viral dynamic studies are very crude and inefficient. In this paper, we review the statistical methods and mathematical models for HIV dynamic data analysis developed in recent years. We also address some practical issues and share our experiences in the design and analysis of viral dynamic studies. Some principles and guidelines for the design and analysis of viral dynamic studies are provided. The methodologies reviewed in this paper are also applicable to studies of other viruses such as hepatitis B virus or hepatitis C virus. We also pose some challenging statistical problems in this area in order to stimulate further study by the statistical research community.


Related Articles

  • Are there adverse consequences of quizzing during informed consent for HIV research? Sugarman, J.; Cornell, A.; Donnell, D.; Liu, T. Y.; Rose, S.; Celentano, D.; Jackson, B.; Aramrattana, A.; Wei, L.; Shao, Y.; Liping, F.; Baoling, R.; Dye, B.; Metzger, D. // Journal of Medical Ethics;Nov2011, Vol. 37 Issue 11, p693 

    Introduction While quizzing during informed consent for research to ensure understanding has become commonplace, it is unclear whether the quizzing itself is problematic for potential participants. In this study, we address this issue in a multinational HIV prevention research trial enrolling...

  • HIV vaccine shows some success in Thailand. Leslie, Joey // Out & About;Oct2009, Vol. 8 Issue 10, p20 

    The article discusses the study which demonstrates the result of Phase III clinical trial demonstrating the safety and modest effectiveness of investigational HIV vaccine to prevent infection in Thailand. It notes that the result released by the U.S. Army Surgeon General showed that ALVACReg HIV...

  • Clinical Trials in New Europe. DOIG, AL // Bio-IT World;Jan2009, Vol. 8 Issue 1, p13 

    The article presents an outlook for clinical trials in New Europe for 2009. The collapse of the Soviet Union is cited as one of the major factors which contributed to the emergence of new opportunity for clinical trials in Europe. An overview of the report from Insight Pharma Reports entitled...

  • Relevance of the clinical impact factor. Blitzkow, Gilson; Estrela, Carlos // Dental Press Endodontics;Jan-Apr2015, Vol. 5 Issue 1, p5 

    The author discusses the importance of systematic literature reviews to analyze clinical impact factors and select accurate and appropriate articles.

  • Investigational protease inhibitor 640385 combats HIV resistance.  // PharmaWatch: Biotechnology;September 2003, Vol. 2 Issue 9, p4 

    Announces the first clinical results for 640385, an investigational HIV protease inhibitor jointly discovered by GlaxoSmithKline PLC and Vertex Pharmaceuticals Inc. Efficacy of the compound in combating HIV virus; Need for the in vitro results shown by the drug to be explored in clinical trials;...

  • Trial and failure.  // Nature;3/1/2007, Vol. 446 Issue 7131, p1 

    The author expresses his view on the failure of the clinical trial of cellulose sulphate vaginal gel against human immunodeficiency virus (HIV) infection. The author shared that microbicide researchers were disappointed with the outcome and a blow to African women. The author suggested that all...

  • European initiative to provide Africa with control of therapeutic development. Clarke, Tom // Nature Reviews Drug Discovery;Nov2003, Vol. 2 Issue 11, p853 

    Reports that the European Commission is inviting applications for a new funding scheme, called the Europe-Development Countries Clinical Trials Partnership (EDCTP), designed to put Africans in control of developing treatments for HIV/AIDS, tuberculosis and malaria in the continent. Skepticism...

  • Randomised controlled trials in Africa of HIV and AIDS descriptive study and spatial distribution. Siegfried, Nandi; Clarke, Mike; Volmink, Jimmy // BMJ: British Medical Journal (International Edition);10/1/2005, Vol. 331 Issue 7519, p742 

    Objectives To identify and describe randomized controlled trials on HIV and AIDS conducted in Africa and to map their spatial distribution using exact geographic coordinates. Design Construction and analysis of a database of trials conducted wholly or partly in Africa and reported before 2004....

  • Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in Western Kenya. Shaffer, D. N.; Yebei, V. N.; Ballidawa, J. B.; Sidle, J. E.; Greene, J. Y.; Meslin, E. M.; Kimaiyo, S. J. N.; Tierney, W. M. // Journal of Medical Ethics;Jan2006, Vol. 32 Issue 1, p55 

    Objectives: To describe the concerns and priorities of key stakeholders in a developing country regarding ethical obligations held by researchers and perceptions of equity or "what is fair" for study participants in an HIV/AIDS clinical drug trial.Design: Qualitative...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics